Table 2.

Patient Demographics, aGvHD grade and response

Disease	Age	Cohort	Graft source	Donor	Conditioning	aGVHD grade Dx	Rx Baseline	aGVHD at d0	aGVHD d28	D28 response	d90 PDN	Additional agent d90	Survival d100	Survival d180
MDS Complex	73	1	BM	MUD	BuFlu	IIB GI d51	PDN 2/kg, Tac B&B	IIB SR	1B	Y	70mg	none	Y	Y
MDS Complex	63	1	PBSC	MUD	BuCy	IIB GI d145	PDN 2/kg, Tac B&B	IIIB HR	IIB	Y	40mg	Rux	Y	N
PV/Myelofibrosis	60	1	PBSC	MRD	BuFlu	IIC GI, skin, liver d268	PDN	IIC HR	0	Y	15mg	none	Y	Y
AML	48	1	BM	MUD	BuCy	1B SR aGvHD d53	PDN 2mg/kg, ECP TacRux	1B SR	0	Y	0	Rux	Y	Y
T-NHL	65	1	PBSC	HAPLO	FluCyTBI	IIC 2 weeks post Nivolumab	PDN 2mg/kg, Rux	IIC SR	IA	Y	10mg	none	Y	Y
AML	42	2	PBSC	MUD	BuCy	IIB skin, GI d31	MPD 1.6/kg, Tac B&B	IIB HR	0	Y	0	none	Y	Y
AML	57	2	BM	MRD	BuCy	IIB d30	PDN 2/kg, Tac Rux	IIC SR	0	Y	10mg	none	Y	Y
AML	58	2	BM	MRD	BuCy	IIIC d346	MPD 1.6/kg, Tac B&B	IIB HR	IIB	N	90mg	Rux	Y	N
AML	35	2	UCB	UCB	FluCyThio	IIB d20	CSAMPD 1.6mg/kg	IIB HR	IIB	N	45mg	none	Y	N
Myelofibrosis	51	2	BM	MUD	BuFluATG	IIIC d97	MPD 1.6mg/kg, Tac B&B	IIIC SR	IV	N	NA	n/a	N	N

AML = acute myeloid leukemia, MDS = Myelodysplastic syndromes, PV = polycythemia vera, T-NHL = T-cell non-Hodgkin lymphoma, MPD = methylprednisolone, PDN=prednisone, Rux= Ruxolitinib,Tac=tacrolimus, B&B= budesonide and beclomethasone, ECP=extracorporeal photopheresis, Bu=busulfan, Cy=Cytoxan, D=Day, Flu=fludarabine, Thio=thiotepa, SR= steroid refractory, HR=high risk, BM=bone marrow, PBSC= Peripheral blood stem cell, UCB=Umbilical Cord Blood, MUD= Matched Unrelated Donor, MRD= Matched Related Donor